.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,261,774

« Back to Dashboard

Details for Patent: 6,261,774

Title: Truncation selex method
Abstract:This invention is directed to a method for identifying nucleic acid ligands by the SELEX method wherein the participation of fixed sequences is eliminated or minimized.
Inventor(s): Pagratis; Nikos (Boulder, CO), Gold; Larry (Boulder, CO), Shtatland; Timur (Boulder, CO), Javornik; Brenda (Boulder, CO)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Filing Date:Mar 24, 1999
Application Number:09/275,850
Claims:1. A method for identifying nucleic acid ligands of a target molecule from a candidate mixture comprised of single stranded nucleic acids each having a region of randomized sequence and a region of fixed sequence, said method comprising:

a) preparing a candidate mixture of single-stranded nucleic acids wherein each nucleic acid member of said candidate mixture comprises a region of randomized sequence and a region of fixed sequence;

b) annealing oligonucleotides to the fixed sequences that are complementary to said fixed sequences to form duplex regions, wherein said fixed sequences of said duplex regions are unavailable for binding to said target;

c) contacting said candidate mixture with said target molecule;

d) partitioning the nucleic acids having an increased affinity to the target molecule relative to the candidate mixture from the remainder of the candidate mixture; and

e) amplifying the increased affinity nucleic acids, in vitro, to yield a ligand-enriched mixture of nucleic acids whereby nucleic acid ligands of the target molecule are identified.

2. A method for identifying nucleic acid ligands of a target molecule from a candidate mixture comprised of single stranded nucleic acids each having a region of randomized sequence and one or more regions of fixed sequences, said method comprising:

a) preparing a candidate mixture of single-stranded nucleic acids wherein each nucleic acid member of said candidate mixture comprises a region of randomized sequence and one or more regions of fixed sequences;

b) contacting said candidate mixture with said target molecule;

c) partitioning the nucleic acids having an increased affinity to the target molecule relative to the candidate mixture from the remainder of the candidate mixture;

d) amplifying the increased affinity nucleic acids, in vitro, to yield a ligand-enriched mixture of nucleic acids;

e) replacing said one or more regions of fixed sequences with a different one or more regions of fixed sequences, whereby the participation of any given fixed sequence in binding to the target is minimized; and

f) repeating steps b)-d), whereby nucleic acid ligands of the target molecule are identified.

3. A method for identifying nucleic acid ligands of a target molecule from a candidate mixture comprised of single stranded nucleic acids each having a region of randomized sequence, said method comprising:

a) contacting said candidate mixture with said target molecule;

b) partitioning the nucleic acids having an increased affinity to the target molecule relative to the candidate mixture from the remainder of the candidate mixture;

c) hybridizing the nucleic acids partitioned in step b) with a library of single stranded nucleic acids that are complementary to the single stranded nucleic acids of the candidate mixture, wherein each nucleic acid member of the complementary library has a fixed region, and wherein the fixed region facilitates amplification of the nucleic acids partitioned in step b);

d) amplifying the nucleic acids that hybridized to a nucleic acid in the complementary library whereby increased affinity nucleic acid ligands of the target molecule are produced, wherein the increased affinity nucleic acid ligands further comprise said fixed region that facilitates amplification; and

e) cleaving said increased affinity nucleic acids to remove said fixed region that facilitates amplification whereby nucleic acid ligands of the target molecule are identified.

4. The method of claim 3 further comprising repeating steps a) through e).

5. The method of claim 3 wherein said candidate mixture is comprised of RNA.

6. The method of claim 3 wherein said candidate mixture is comprised of DNA.

7. The method of claim 5 wherein said RNA acids are modified ribonucleic acids.

8. The method of claim 6 wherein said DNA acids are modified ribonucleic acids.

9. The method of claim 3 wherein the fixed regions of the increased affinity nucleic acids are cleaved by a restriction enzyme.

10. The method of claim 9 wherein the restriction enzyme is RNase H.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc